2-Fluoropyrimidine (BioDeep_00000173282)
human metabolite blood metabolite
代谢物信息卡片
pyrimidine, 2-fluoro-
化学式: C4H3FN2 (98.02802499999999)
中文名称: 2-氟嘧啶
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1=CN=C(N=C1)F
InChI: InChI=1S/C4H3FN2/c5-4-6-2-1-3-7-4/h1-3H
数据库引用编号
5 个数据库交叉引用编号
- PubChem: 141643
- HMDB: HMDB0245132
- Wikipedia: Fluoropyrimidine
- chemspider: 124968
- CAS: 31575-35-6
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Giacomo Allegrini, Teresa Di Desidero, Maria Teresa Barletta, Anna Fioravanti, Paola Orlandi, Bastianina Canu, Silvio Chericoni, Fotios Loupakis, Antonello Di Paolo, Gianluca Masi, Andrea Fontana, Sara Lucchesi, Giada Arrighi, Mario Giusiani, Andrea Ciarlo, Giovanni Brandi, Romano Danesi, Robert S Kerbel, Alfredo Falcone, Guido Bocci. Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers.
Angiogenesis.
2012 Jun; 15(2):275-86. doi:
10.1007/s10456-012-9260-6. [PMID: 22382585] - Tsuyoshi Shoji, Makoto Sonobe, Hiroaki Sakai, Takuji Fujinaga, Toshihiko Sato, Fengshi Chen, Ryo Miyahara, Toru Bando, Hiromi Wada, Hiroshi Date. Pharmacokinetic study of weekly (days 1-5) low-dose S-1 in patients with non-small-cell lung cancer.
Reviews on recent clinical trials.
2012 May; 7(2):167-72. doi:
10.2174/157488712800100260. [PMID: 22353201] - Koh Miura, Tetsuhiko Shirasaka, Hiroki Yamaue, Iwao Sasaki. S-1 as a core anticancer fluoropyrimidine agent.
Expert opinion on drug delivery.
2012 Mar; 9(3):273-86. doi:
10.1517/17425247.2012.652945. [PMID: 22235991] - M Takagi, K Sakata, M Someya, Y Matsumoto, H Tauchi, M Hareyama, M Fukushima. The combination of hyperthermia or chemotherapy with gimeracil for effective radiosensitization.
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].
2012 Mar; 188(3):255-61. doi:
10.1007/s00066-011-0043-6. [PMID: 22322869] - Masanori Hasegawa, Akira Miyajima, Takeo Kosaka, Yota Yasumizu, Nobuyuki Tanaka, Takahiro Maeda, Suguru Shirotake, Hiroki Ide, Eiji Kikuchi, Mototsugu Oya. Low-dose docetaxel enhances the sensitivity of S-1 in a xenograft model of human castration resistant prostate cancer.
International journal of cancer.
2012 Jan; 130(2):431-42. doi:
10.1002/ijc.26012. [PMID: 21351099] - Chad W Schmiedt, Corey F Saba, Kimberly G Freeman, Gaylen L Edwards. Assessment of plasma uracil-to-dihydrouracil concentration ratio as an indicator of dihydropyrimidine dehydrogenase activity in clinically normal dogs and dogs with neoplasia or renal insufficiency.
American journal of veterinary research.
2012 Jan; 73(1):119-24. doi:
10.2460/ajvr.73.1.119. [PMID: 22204297] - Godefridus J Peters, Auke D Adema, Irene V Bijnsdorp, Marit L Sandvold. Lipophilic prodrugs and formulations of conventional (deoxy)nucleoside and fluoropyrimidine analogs in cancer.
Nucleosides, nucleotides & nucleic acids.
2011 Dec; 30(12):1168-80. doi:
10.1080/15257770.2011.607143. [PMID: 22132972] - Dohan Weeraratne, Alin Chen, Jason J Pennucci, Chi-Yuan Wu, Kathy Zhang, Jacqueline Wright, Juan José Pérez-Ruixo, Bing-Bing Yang, Arunan Kaliyaperumal, Shalini Gupta, Steven J Swanson, Narendra Chirmule, Marta Starcevic. Immunogenicity of panitumumab in combination chemotherapy clinical trials.
BMC clinical pharmacology.
2011 Nov; 11(?):17. doi:
10.1186/1472-6904-11-17. [PMID: 22070868] - C E de Bock, M B Garg, N Scott, J A Sakoff, F E Scorgie, S P Ackland, L F Lincz. Association of thymidylate synthase enhancer region polymorphisms with thymidylate synthase activity in vivo.
The pharmacogenomics journal.
2011 Aug; 11(4):307-14. doi:
10.1038/tpj.2010.43. [PMID: 20531375] - Kentaro Sudo, Taketo Yamaguchi, Takeshi Ishihara, Kazuyoshi Nakamura, Taro Hara, Tadamichi Denda, Katsunobu Tawada, Toshiyuki Imagumbai, Hitoshi Araki, Mitsuhiro Sakai, Kazuo Hatano, Hiroyuki Kawakami, Takashi Uno, Hisao Ito, Osamu Yokosuka. Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer.
International journal of radiation oncology, biology, physics.
2011 May; 80(1):119-25. doi:
10.1016/j.ijrobp.2010.01.027. [PMID: 20605363] - Chen Guang Yang, Joseph Ciccolini, Aurore Blesius, Laetitia Dahan, Danielle Bagarry-Liegey, Caroline Brunet, Arthur Varoquaux, Nicolas Frances, Hafedh Marouani, Antoine Giovanni, Rose-Marie Ferri-Dessens, Mohamed Chefrour, Roger Favre, Florence Duffaud, Jean-François Seitz, Michel Zanaret, Bruno Lacarelle, Cédric Mercier. DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity.
Cancer chemotherapy and pharmacology.
2011 Jan; 67(1):49-56. doi:
10.1007/s00280-010-1282-4. [PMID: 20204365] - Masao Kobayakawa, Yasushi Kojima. Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies.
OncoTargets and therapy.
2011; 4(?):193-201. doi:
10.2147/ott.s19059. [PMID: 22162925] - Takao Tamura, Akiko Kuwahara, Kaori Kadoyama, Motohiro Yamamori, Kohshi Nishiguchi, Tsubasa Inokuma, Yoshiji Takemoto, Naoko Chayahara, Tatsuya Okuno, Ikuya Miki, Yoshimi Fujishima, Toshiyuki Sakaeda. Effects of bolus injection of 5-fluorouracil on steady-state plasma concentrations of 5-fluorouracil in Japanese patients with advanced colorectal cancer.
International journal of medical sciences.
2011; 8(5):406-12. doi:
10.7150/ijms.8.406. [PMID: 21750645] - Rossana Berardi, Azzurra Onofri, Mirco Pistelli, Elena Maccaroni, Mario Scartozzi, Chiara Pierantoni, Stefano Cascinu. Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer.
Core evidence.
2010 Oct; 5(?):61-76. doi:
10.2147/ce.s7035. [PMID: 21042543] - C O Michie, M Sakala, I Rivans, M W J Strachan, S Clive. The frequency and severity of capecitabine-induced hypertriglyceridaemia in routine clinical practice: a prospective study.
British journal of cancer.
2010 Aug; 103(5):617-21. doi:
10.1038/sj.bjc.6605807. [PMID: 20664584] - Heidi Schwarzenbach, Eray Goekkurt, Klaus Pantel, Daniela E Aust, Jan Stoehlmacher. Molecular analysis of the polymorphisms of thymidylate synthase on cell-free circulating DNA in blood of patients with advanced colorectal carcinoma.
International journal of cancer.
2010 Aug; 127(4):881-8. doi:
10.1002/ijc.25096. [PMID: 19998340] - S Antoun, V E Baracos, L Birdsell, B Escudier, M B Sawyer. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology.
2010 Aug; 21(8):1594-1598. doi:
10.1093/annonc/mdp605. [PMID: 20089558] - L J M Mekenkamp, M Koopman, S Teerenstra, J H J M van Krieken, L Mol, I D Nagtegaal, C J A Punt. Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases.
British journal of cancer.
2010 Jul; 103(2):159-64. doi:
10.1038/sj.bjc.6605737. [PMID: 20551951] - Jan Gerard Maring, Floris M Wachters, Monique Slijfer, J Marina Maurer, H Marike Boezen, Donald R A Uges, Elisabeth G E de Vries, Harry J M Groen. Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism.
European journal of clinical pharmacology.
2010 Jun; 66(6):611-7. doi:
10.1007/s00228-010-0799-0. [PMID: 20213492] - Xiaofan Zhang, Julia Li Zhong, Wei Liu, Zuhua Gao, Xia Xue, Pan Yue, Limei Wang, Cuirong Zhao, Wenfang Xu, Xianjun Qu. N(3)-o-toluyl-fluorouracil inhibits human hepatocellular carcinoma cell growth via sustained release of 5-FU.
Cancer chemotherapy and pharmacology.
2010 May; 66(1):11-9. doi:
10.1007/s00280-009-1128-0. [PMID: 19756602] - Bunzo Nakata, Ryosuke Amano, Shigetomi Nakao, Tatsuro Tamura, Osamu Shinto, Toshiki Hirakawa, Yoshihiro Okita, Nobuya Yamada, Kosei Hirakawa. Plasma pharmacokinetics after combined therapy of gemcitabine and oral S-1 for unresectable pancreatic cancer.
Journal of experimental & clinical cancer research : CR.
2010 Feb; 29(?):15. doi:
10.1186/1756-9966-29-15. [PMID: 20181235] - T Trarbach, M Moehler, V Heinemann, C-H Köhne, M Przyborek, C Schulz, V Sneller, G Gallant, S Kanzler. Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer.
British journal of cancer.
2010 Feb; 102(3):506-12. doi:
10.1038/sj.bjc.6605507. [PMID: 20068564] - Hei-Cheul Jeung, Sun Young Rha, Sang Joon Shin, Joong Bae Ahn, Sung Hoon Noh, Jae Kyung Roh, Hyun Cheol Chung. Two dosages of oral fluoropyrimidine S-1 of 35 and 40 mg/m2 bid: comparison of the pharmacokinetic profiles in Korean patients with advanced gastric cancer.
Japanese journal of clinical oncology.
2010 Jan; 40(1):29-35. doi:
10.1093/jjco/hyp124. [PMID: 19880858] - M Wasif Saif, Adrienne Choma, Salvatore J Salamone, Edward Chu. Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes.
Journal of the National Cancer Institute.
2009 Nov; 101(22):1543-52. doi:
10.1093/jnci/djp328. [PMID: 19841331] - Marnix G E H Lam, Tjitske B Bosma, Peter P van Rijk, Bernard A Zonnenberg. (188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study.
European journal of nuclear medicine and molecular imaging.
2009 Sep; 36(9):1425-33. doi:
10.1007/s00259-009-1119-8. [PMID: 19319526] - Elisa Gálvez-Muñoz, Javier Gallego-Plazas, Verónica Gonzalez-Orozco, Francisco Menarguez-Pina, José A Ruiz-Maciá, Miguel A Morcillo. Hepatoid adenocarcinoma of the stomach - a different histology for not so different gastric adenocarcinoma: a case report.
International seminars in surgical oncology : ISSO.
2009 Aug; 6(?):13. doi:
10.1186/1477-7800-6-13. [PMID: 19674468] - L C Scott, T R J Evans, J Cassidy, S Harden, J Paul, R Ullah, V O'Brien, R Brown. Cytokeratin 18 in plasma of patients with gastrointestinal adenocarcinoma as a biomarker of tumour response.
British journal of cancer.
2009 Aug; 101(3):410-7. doi:
10.1038/sj.bjc.6605175. [PMID: 19603019] - Bhim Bali Prasad, Khushaboo Tiwari, Meenakshi Singh, Piyush Sindhu Sharma, Amit Kumar Patel, Shrinkhala Srivastava. Ultratrace analysis of uracil and 5-fluorouracil by molecularly imprinted polymer brushes grafted to silylated solid-phase microextraction fiber in combination with complementary molecularly imprinted polymer-based sensor.
Biomedical chromatography : BMC.
2009 May; 23(5):499-509. doi:
10.1002/bmc.1145. [PMID: 19101922] - Andre Mihaljevic, Peter Büchler, Jan Harder, Ralf Hofheinz, Michael Gregor, Stephan Kanzler, Wolff Schmiegel, Volker Heinemann, Esther Endlicher, Günter Klöppel, Thomas Seufferlein, Michael Geissler. A prospective, non-randomized phase II trial of Trastuzumab and Capecitabine in patients with HER2 expressing metastasized pancreatic cancer.
BMC surgery.
2009 Jan; 9(?):1. doi:
10.1186/1471-2482-9-1. [PMID: 19133157] - Per Byström, Karin Björkegren, Anders Larsson, Linda Johansson, Ake Berglund. Serum vitamin B12 and folate status among patients with chemotherapy treatment for advanced colorectal cancer.
Upsala journal of medical sciences.
2009; 114(3):160-4. doi:
10.1080/03009730903027172. [PMID: 19736606] - A D Adema, I V Bijnsdorp, M L Sandvold, H M Verheul, G J Peters. Innovations and opportunities to improve conventional (deoxy)nucleoside and fluoropyrimidine analogs in cancer.
Current medicinal chemistry.
2009; 16(35):4632-43. doi:
10.2174/092986709789878229. [PMID: 19903145] - Haijun Zhong, Yiping Zhang, Shenglin Ma, Jie-Er Ying, Yunshan Yang, Dong Yong, Xiaosheng Hang, Qing Sun, Baoliang Zhong, Daoyuan Wang. Docetaxel plus oxaliplatin (DOCOX) as a second-line treatment after failure of fluoropyrimidine and platinum in Chinese patients with advanced gastric cancer.
Anti-cancer drugs.
2008 Nov; 19(10):1013-8. doi:
10.1097/cad.0b013e328314b5ab. [PMID: 18827567] - Aiko Tsuda, Junshin Fujiyama, Akiko Miki, Satoko Hori, Hisakazu Ohtani, Yasufumi Sawada. The first case of phenytoin intoxication associated with the concomitant use of phenytoin and TS-1, a combination preparation of tegafur, gimeracil, and oteracil potassium.
Cancer chemotherapy and pharmacology.
2008 Aug; 62(3):427-32. doi:
10.1007/s00280-007-0621-6. [PMID: 18026730] - Tetsuro Sohda, Takayuki Hanano, Hisanori Miyamoto, Yoko Kitano, Kaoru Iwata, Masanori Yokoyama, Makoto Irie, Yasuaki Takeyama, Satoshi Shakado, Shotaro Sakisaka. Spontaneous rupture of metastatic alpha-fetoprotein-producing gastric cancer of the liver.
Hepatology international.
2008 06; 2(2):258-61. doi:
10.1007/s12072-008-9072-3. [PMID: 19669313] - W S Siegel-Lakhai, A S Zandvliet, A D R Huitema, M M Tibben, G Milano, V Girre, V Diéras, A King, E Richmond, J Wanders, J H Beijnen, J H M Schellens. A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours.
British journal of cancer.
2008 Apr; 98(8):1320-6. doi:
10.1038/sj.bjc.6604300. [PMID: 18414469] - Walter M Stadler, Apurva A Desai, David I Quinn, Ronald Bukowski, Bernard Poiesz, Carl G Kardinal, Nancy Lewis, Alex Makalinao, Peter Murray, Frank M Torti. A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma.
Cancer chemotherapy and pharmacology.
2008 Apr; 61(4):689-94. doi:
10.1007/s00280-007-0524-6. [PMID: 17569043] - Martijn van Essen, Eric P Krenning, Boen L Kam, Wouter W de Herder, Maarten O van Aken, Dik J Kwekkeboom. Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours.
European journal of nuclear medicine and molecular imaging.
2008 Apr; 35(4):743-8. doi:
10.1007/s00259-007-0688-7. [PMID: 18188559] - M-C Etienne-Grimaldi, J-M Cardot, E François, N Renée, J-Y Douillard, E Gamelin, G Milano. Chronopharmacokinetics of oral tegafur and uracil in colorectal cancer patients.
Clinical pharmacology and therapeutics.
2008 Mar; 83(3):413-5. doi:
10.1038/sj.clpt.6100297. [PMID: 17637782] - Takeharu Yamanaka, Shigemi Matsumoto, Satoshi Teramukai, Ryota Ishiwata, Yoji Nagai, Masanori Fukushima. Safety evaluation of oral fluoropyrimidine S-1 for short- and long-term delivery in advanced gastric cancer: analysis of 3,758 patients.
Cancer chemotherapy and pharmacology.
2008 Feb; 61(2):335-43. doi:
10.1007/s00280-007-0595-4. [PMID: 17922276] - Nobutaka Nagai, Keiji Mukai, Eiji Hirata, Hong Hua Jin, Masaaki Komatsu, Mayu Yunokawa. UFT and its metabolite gamma-butyrolactone (GBL) inhibit angiogenesis induced by vascular endothelial growth factor in advanced cervical carcinoma.
Medical oncology (Northwood, London, England).
2008; 25(2):214-21. doi:
10.1007/s12032-007-9023-1. [PMID: 17968681] - Yasunori Emi, Yasushi Sumiyoshi, Eiji Oki, Yoshihiro Kakeji, Yousuke Fukui, Yoshihiko Maehara. Pharmacokinetics of gamma-hydroxybutylic acid (GHB) and gamma-butyrolactone (GBL), the anti-angiogenic metabolites of oral fluoropyrimidine UFT, in patients with gastric cancer.
Fukuoka igaku zasshi = Hukuoka acta medica.
2007 Dec; 98(12):418-24. doi:
. [PMID: 18260367] - Ken Sasaki, Shoji Natsugoe, Kuniaki Aridome, Sumiya Ishigami, Shuichi Hokita, Takashi Aikou. The successfully curative treatment of advanced gastric adenocarcinoma with multiple liver metastases and paraaortic lymph node metastases by salvage operation following the biweekly paclitaxel and S-1 combination chemotherapy: a case report.
Hepato-gastroenterology.
2007 Dec; 54(80):2421-4. doi:
NULL. [PMID: 18265679] - G Pentheroudakis, P Pappas, V Golfinopoulos, G Fountzilas, M Nikolaidou, V A Boumba, T Vougiouklakis, L Nikiforidis, E Tzamakou, O Siarabi, M Marselos, N Pavlidis. Weekday on-weekend off oral capecitabine: a phase I study of a continuous schedule better simulating protracted fluoropyrimidine therapy.
Cancer chemotherapy and pharmacology.
2007 Oct; 60(5):733-9. doi:
10.1007/s00280-007-0419-6. [PMID: 17333194] - Mitsugu Kochi, Masashi Fujii, Noriaki Kanamori, Teruo Kaiga, Kazuo Aizaki, Toru Takahashi, Tadatoshi Takayama. Effect of gastrectomy on the pharmacokinetics of S-1, an oral fluoropyrimidine, in resectable gastric cancer patients.
Cancer chemotherapy and pharmacology.
2007 Oct; 60(5):693-701. doi:
10.1007/s00280-007-0415-x. [PMID: 17690883] - Rupert Bartsch, Guenther G Steger, Birgit Forstner, Catharina Wenzel, Ursula Pluschnig, Blanka Rizovski, Gabriela Altorjai, Christoph C Zielinski, Robert M Mader. Expression of thymidine phosphorylase in peripheral blood cells of breast cancer patients is not increased by paclitaxel.
BMC clinical pharmacology.
2007 Jul; 7(?):7. doi:
10.1186/1472-6904-7-7. [PMID: 17640356] - Hiromitsu Takeyama, Hirozumi Sawai, Takehiro Wakasugi, Hiroki Takahashi, Yoichi Matsuo, Nobuo Ochi, Akira Yasuda, Mikinori Sato, Yuji Okada, Hitoshi Funahashi, Yoshimi Akamo, Tadao Manabe. Successful paclitaxel-based chemotherapy for an alpha-fetoprotein-producing gastric cancer patient with multiple liver metastases.
World journal of surgical oncology.
2007 Jul; 5(?):79. doi:
10.1186/1477-7819-5-79. [PMID: 17634124] - G P Stathopoulos, J Koutantos, H Lazaki, S K Rigatos, J Stathopoulos, G Deliconstantinos. Capecitabine (Xeloda) as monotherapy in advanced breast and colorectal cancer: effectiveness and side-effects.
Anticancer research.
2007 May; 27(3B):1653-6. doi:
NULL. [PMID: 17595791] - Muhammad Wasif Saif, Mohammad Houman Fekrazad, Leslie Ledbetter, Robert B Diasio. Hypokalemia secondary to capecitabine: a hidden toxicity?.
Therapeutics and clinical risk management.
2007 Mar; 3(1):177-80. doi:
10.2147/tcrm.2007.3.1.177. [PMID: 18360625] - Erick Gamelin, Michèle Boisdron-Celle, Alain Morel. [Detection of dihydropyrimidine dehydrogenase deficiency before treatment by fluoropyrimidines].
Therapie.
2007 Mar; 62(2):99-103. doi:
10.2515/therapie:2007023. [PMID: 17582309] - Ena Segota, Tarek Mekhail, Thomas Olencki, Thomas E Hutson, Robert Dreicer, Brenda Wacker, Bruno Osterwalder, Paul Elson, Ming Zhou, Ronald M Bukowski. Phase II trial of capecitabine and rHu-interferon-alpha-2a in patients with metastatic renal cell carcinoma, limited efficacy, and moderate toxicity.
Urologic oncology.
2007 Jan; 25(1):46-52. doi:
10.1016/j.urolonc.2006.02.016. [PMID: 17208138] - Joseph Ciccolini, Cédric Mercier, Alexandre Evrard, Laetitia Dahan, Jean-Christophe Boyer, Florence Duffaud, Karine Richard, Carmelo Blanquicett, Gérard Milano, Aurore Blesius, Alain Durand, Jean-François Seitz, Roger Favre, Bruno Lacarelle. A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy.
Therapeutic drug monitoring.
2006 Oct; 28(5):678-85. doi:
10.1097/01.ftd.0000245771.82720.c7. [PMID: 17038885] - Walter M Stadler, Susan Halabi, Brian Rini, Marc S Ernstoff, Enrique Davila, Joel Picus, Robert Barrier, Eric J Small. A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008.
Cancer.
2006 Sep; 107(6):1273-9. doi:
10.1002/cncr.22117. [PMID: 16909426] - Yasuhide Yamada. [Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil].
Gan to kagaku ryoho. Cancer & chemotherapy.
2006 Jun; 33 Suppl 1(?):37-41. doi:
. [PMID: 16897970] - Hideyuki Akaza. [The possibility of S-1 for the treatment of patients with urological cancers].
Gan to kagaku ryoho. Cancer & chemotherapy.
2006 Jun; 33 Suppl 1(?):236-8. doi:
NULL. [PMID: 16898009] - Koichi Hirata, Noboru Horikoshi, Kazusaku Tominaga, Keisuke Sohma, Koji Yamaguchi, Minoru Okazaki, Tomohisa Furuhata, Kazuaki Sasaki, Yasuyuki Nakano, Hikaru Ishizuka, Yasuhide Yamada, Shinji Uno, Tetsuo Taguchi, Susumu Yamamitsu, Tetsuhiko Shirasaka. [Pharmacokinetics of S-1].
Gan to kagaku ryoho. Cancer & chemotherapy.
2006 Jun; 33 Suppl 1(?):27-35. doi:
NULL. [PMID: 16897969] - Javier Pemán, Miguel Salavert, Emilia Cantón, Isidro Jarque, Eva Romá, Rafael Zaragoza, Angel Viudes, Miguel Gobernado. Voriconazole in the management of nosocomial invasive fungal infections.
Therapeutics and clinical risk management.
2006 Jun; 2(2):129-58. doi:
10.2147/tcrm.2006.2.2.129. [PMID: 18360588] - Angelos K Koutras, Ioannis G Habeos, Apostolos G Vagenakis, Haralabos P Kalofonos. Capecitabine-induced hypertriglyceridemia: a report of two cases.
Anticancer research.
2006 May; 26(3B):2249-51. doi:
". [PMID: 16821596] - R Sharma, L Rivory, P Beale, S Ong, L Horvath, S J Clarke. A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer.
British journal of cancer.
2006 Apr; 94(7):964-8. doi:
10.1038/sj.bjc.6603049. [PMID: 16552436] - Young Ju Noh, Won Sik Choi, Jong Hoon Kim, Jin Cheon Kim, Chang Sik Yu, Hee Cheol Kim, Tae Won Kim, Heung Moon Chang, Min Hee Ryu, Seung Do Ahn, Sang-wook Lee, Seong Soo Shin, Jung Eun Lee, Eun Kyung Choi. Optimal timing for the administration of capecitabine with preoperative chemoradiation for locally advanced rectal cancer.
Cancer research and treatment.
2006 Feb; 38(1):30-4. doi:
10.4143/crt.2006.38.1.30. [PMID: 19771256] - Gaëlle Remaud, Michèle Boisdron-Celle, Catherine Hameline, Alain Morel, Erick Gamelin. An accurate dihydrouracil/uracil determination using improved high performance liquid chromatography method for preventing fluoropyrimidines-related toxicity in clinical practice.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2005 Sep; 823(2):98-107. doi:
10.1016/j.jchromb.2005.05.044. [PMID: 16027050] - Jae-Yong Cho, Ji-Sun Nam, Mi-Suk Park, Jeong-Sik Yu, Yong-Han Paik, Se-Joon Lee, Dong-Ki Lee, Dong-Sup Yoon. A Phase II study of capecitabine combined with gemcitabine in patients with advanced gallbladder carcinoma.
Yonsei medical journal.
2005 Aug; 46(4):526-31. doi:
10.3349/ymj.2005.46.4.526. [PMID: 16127778] - Kong M Li, Laurent P Rivory, Stephen J Clarke. Rapid quantitation of plasma 2'-deoxyuridine by high-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometry and its application to pharmacodynamic studies in cancer patients.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2005 Jun; 820(1):121-30. doi:
10.1016/j.jchromb.2005.03.008. [PMID: 15866500] - Yuji Ueda, Hisakazu Yamagishi, Daisuke Ichikawa, Jun Morii, Kinya Koizumi, Naoki Kakihara, Masataka Shimotsuma, Atsushi Takenaka, Tetsuro Yamashita, Hideaki Kurioka, Masahiko Nishiyama, Satoshi Morita, Kanae Nakamura, Junichi Sakamoto. Phase I study of a combination of s-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer.
Oncology.
2005; 69(3):261-8. doi:
10.1159/000088072. [PMID: 16138002] - Kazumasa Fujitani, Hiroyuki Narahara, Hiroya Takiuchi, Toshimasa Tsujinaka, Eriko Satomi, Masahiro Gotoh, Motohiro Hirao, Hiroshi Furukawa, Tetsuo Taguchi. Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer.
Oncology.
2005; 69(5):414-20. doi:
10.1159/000089996. [PMID: 16319513] - J S Waters, C Moss, L Pyle, M James, S Hackett, R A'hern, M Gore, T Eisen. Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma.
British journal of cancer.
2004 Nov; 91(10):1763-8. doi:
10.1038/sj.bjc.6602209. [PMID: 15505625] - Hao Jiang, Jing Lu, Ji Jiang, Pei Hu. Important role of the dihydrouracil/uracil ratio in marked interpatient variations of fluoropyrimidine pharmacokinetics and pharmacodynamics.
Journal of clinical pharmacology.
2004 Nov; 44(11):1260-72. doi:
10.1177/0091270004268911. [PMID: 15496644] - Takahiro Niinobu, Makoto Yamamoto, Masaaki Taniguchi, Tadahide Kotobuki, Atsuhiro Otsuka. [A case of liver metastasis of gastric cancer responding well to TS-1].
Gan to kagaku ryoho. Cancer & chemotherapy.
2004 Oct; 31(11):1674-7. doi:
. [PMID: 15553680] - Peeter Padrik, Krista Leppik, Andrus Arak. Combination therapy with capecitabine and interferon alfa-2A in patients with advanced renal cell carcinoma: a phase II study.
Urologic oncology.
2004 Sep; 22(5):387-92. doi:
10.1016/j.urolonc.2003.11.014. [PMID: 15464918] - M Aoun. [Voriconazole: a new weapon against invasive fungal infections].
Revue medicale de Bruxelles.
2004 Jun; 25(3):166-71. doi:
. [PMID: 15291449] - Yuji Ueda, Hisakazu Yamagishi, Tetsuro Yamashita, Norio Itoh, Hirosumi Itoi, Tetsuhiko Shirasaka, Jaffer A Ajani. S-1-induced, prolonged complete regression of lung metastasis from gastric cancer refractory to 5'-DFUR: a case report with pharmacokinetic study.
Japanese journal of clinical oncology.
2004 May; 34(5):282-6. doi:
10.1093/jjco/hyh044. [PMID: 15231865] - Norbert W Lutz, Belal Naser-Hijazi, Squire Koroma, Martin R Berger, William E Hull. Fluoropyrimidine chemotherapy in a rat model: comparison of fluorouracil metabolite profiles determined by high-field 19F-NMR spectroscopy of tissues ex vivo with therapy response and toxicity for locoregional vs systemic infusion protocols.
NMR in biomedicine.
2004 May; 17(3):101-31. doi:
10.1002/nbm.880. [PMID: 15137037] - R Morant, J Bernhard, D Dietrich, S Gillessen, M Bonomo, M Borner, J Bauer, T Cerny, C Rochlitz, M Wernli, A Gschwend, S Hanselmann, F Hering, H-P Schmid. Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial.
British journal of cancer.
2004 Apr; 90(7):1312-7. doi:
10.1038/sj.bjc.6601673. [PMID: 15054447] - Yasutada Akiba, Yoshiyuki Yamagishi, Syuka Mori, Tomoki Ueda, Junji Suzuki, Naoki Hosoe, Mikiko Izumiya, Hiromasa Takaishi, Hiroshi Nagata, Toshihumi Hibi, Hiromasa Ishii. [A case of recurrent pleural effusion and positive cytology of advanced gastric cancer treated by TS-1 plus weekly taxane as second-line chemotherapy].
Gan to kagaku ryoho. Cancer & chemotherapy.
2004 Mar; 31(3):453-6. doi:
. [PMID: 15045961] - Joseph Ciccolini, Alexandre Evrard, Pierre Cuq. Thymidine phosphorylase and fluoropyrimidines efficacy: a Jekyll and Hyde story.
Current medicinal chemistry. Anti-cancer agents.
2004 Mar; 4(2):71-81. doi:
10.2174/1568011043482089. [PMID: 15032715] - Patrick Schöffski. The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors.
Anti-cancer drugs.
2004 Feb; 15(2):85-106. doi:
10.1097/00001813-200402000-00001. [PMID: 15075664] - P A Vasey, L McMahon, J Paul, N Reed, S B Kaye. A phase II trial of capecitabine (Xeloda) in recurrent ovarian cancer.
British journal of cancer.
2003 Nov; 89(10):1843-8. doi:
10.1038/sj.bjc.6601381. [PMID: 14612890] - X Pivot, E Chamorey, E Guardiola, N Magné, A Thyss, J Otto, B Giroux, Z Mouri, M Schneider, G Milano. Phase I and pharmacokinetic study of the association of capecitabine-cisplatin in head and neck cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology.
2003 Oct; 14(10):1578-86. doi:
10.1093/annonc/mdg410. [PMID: 14504061] - Bruno Reigner, Toru Watanabe, Johannes Schüller, Helen Lucraft, Yasutsuna Sasaki, John Bridgewater, Toshiaki Saeki, James McAleer, Masaru Kuranami, Christopher Poole, Mitsunori Kimura, Jayne Monkhouse, Cahit Yorulmaz, Erhard Weidekamm, Susan Grange. Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer.
Cancer chemotherapy and pharmacology.
2003 Sep; 52(3):193-201. doi:
10.1007/s00280-003-0642-8. [PMID: 12783206] - Y Yamada, T Hamaguchi, M Goto, K Muro, Y Matsumura, Y Shimada, K Shirao, S Nagayama. Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil.
British journal of cancer.
2003 Sep; 89(5):816-20. doi:
10.1038/sj.bjc.6601224. [PMID: 12942110] - S J Roffey, S Cole, P Comby, D Gibson, S G Jezequel, A N R Nedderman, D A Smith, D K Walker, N Wood. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human.
Drug metabolism and disposition: the biological fate of chemicals.
2003 Jun; 31(6):731-41. doi:
10.1124/dmd.31.6.731. [PMID: 12756205] - R M Mader, C Schrolnberger, B Rizovski, M Brunner, C Wenzel, G Locker, H G Eichler, M Mueller, G G Steger. Penetration of capecitabine and its metabolites into malignant and healthy tissues of patients with advanced breast cancer.
British journal of cancer.
2003 Mar; 88(5):782-7. doi:
10.1038/sj.bjc.6600809. [PMID: 12618890] - Ake Berglund, Göran Carlsson, Bengt Gustavsson, Jan-Erik Frödin, Peter Ragnhammar, Bengt Glimelius. 5-FU split dose; a phase I/II and pharmacokinetic study of a different schedule of the Nordic regimen in advanced colorectal carcinoma.
Anticancer research.
2003 Mar; 23(2C):1789-94. doi:
NULL. [PMID: 12820460] - Yasutada Akiba, Chikako Watanabe, Yasuhiro Takada, Kotaro Naito, Daisuke Aoki, Makio Mukai, Shinzo Kato, Toshifumi Hibi, Hiromasa Ishii. [A case of type 4 gastric cancer, diagnosed after operation for Krukenberg's tumor, treated by TS-1 plus low-dose cisplatinum].
Gan to kagaku ryoho. Cancer & chemotherapy.
2003 Feb; 30(2):277-81. doi:
NULL. [PMID: 12610879] - Catharina Wenzel, Robert M Mader, Guenther G Steger, Ursula Pluschnig, Gabriela V Kornek, Werner Scheithauer, Gottfried J Locker. Capecitabine treatment results in increased mean corpuscular volume of red blood cells in patients with advanced solid malignancies.
Anti-cancer drugs.
2003 Feb; 14(2):119-23. doi:
10.1097/00001813-200302000-00005. [PMID: 12569298] - Kazuhiko Hayashi, Toshihide Imaizumi, Kazumi Uchida, Hidekazu Kuramochi, Ken Takasaki. High response rates in patients with pancreatic cancer using the novel oral fluoropyrimidine S-1.
Oncology reports.
2002 Nov; 9(6):1355-61. doi:
10.3892/or.9.6.1355. [PMID: 12375048] - T Takechi, A Fujioka, E Matsushima, M Fukushima. Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells.
European journal of cancer (Oxford, England : 1990).
2002 Jun; 38(9):1271-7. doi:
10.1016/s0959-8049(02)00048-5. [PMID: 12044515] - G Di Stefano, C Busi, L Fiume. Floxuridine coupling with lactosaminated human albumin to increase drug efficacy on liver micrometastases.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
2002 Jun; 34(6):439-46. doi:
10.1016/s1590-8658(02)80042-1. [PMID: 12132792] - Shinei Kudo, Jun-Ichi Tanaka, Hiroshi Kashida, Yoshiro Tamegai, Shungo Endo, Hiro-O Yamano. Effectiveness of immunochemotherapy with PSK, a protein-bound polysaccharide, in colorectal cancer and changes of tumor marker.
Oncology reports.
2002 May; 9(3):635-8. doi:
10.3892/or.9.3.635. [PMID: 11956642] - George Pentheroudakis, Chris Twelves. Capecitabine (Xeloda): from the laboratory to the patient's home.
Clinical colorectal cancer.
2002 May; 2(1):16-23. doi:
10.3816/ccc.2002.n.007. [PMID: 12453332] - Nobuhiro Takiguchi, Keiji Koda, Hirokazu Ooshima, Kenji Oda, Hirofumi Suzuki, Rumiko Ishii, Masaru Miyazaki. Dihydropyrimidine dehydrogenase-related enzymes predict efficacy and adverse reactions of UFT1+cisplatin neoadjuvant chemotherapy for gastric cancer.
Anti-cancer drugs.
2002 Apr; 13(4):411-6. doi:
10.1097/00001813-200204000-00010. [PMID: 11984087] - Hao Jiang, Ji Jiang, Pei Hu, Yufang Hu. Measurement of endogenous uracil and dihydrouracil in plasma and urine of normal subjects by liquid chromatography-tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2002 Mar; 769(1):169-76. doi:
10.1016/s1570-0232(02)00009-0. [PMID: 11936689] - R Gieschke, B Reigner, K S Blesch, J L Steimer. Population pharmacokinetic analysis of the major metabolites of capecitabine.
Journal of pharmacokinetics and pharmacodynamics.
2002 Feb; 29(1):25-47. doi:
10.1023/a:1015716617967. [PMID: 12194534] - Osamu Kobayashi, Kazuo Konishi, Masahiro Kanari, Haruhiko Cho, Takaki Yoshikawa, Akira Tsuburaya, Motonori Sairenji, Hisahiko Motohashi. Unusual survival for more than 2 years with peritoneal metastases of gastric cancer.
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association.
2002; 5(1):47-50. doi:
10.1007/s101200200007. [PMID: 12021860] - Catharina Wenzel, Gottfried J Locker, Manuela Schmidinger, Robert Mader, Gero Kramer, Michael Marberger, Michael Rauchenwald, Cristoph C Zielinski, Guenther G Steger. Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2002 Jan; 39(1):48-54. doi:
10.1053/ajkd.2002.29879. [PMID: 11774101] - J F Mata, J M García-Manteiga, M P Lostao, S Fernández-Veledo, E Guillén-Gómez, I M Larrayoz, J Lloberas, F J Casado, M Pastor-Anglada. Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5[Prime]-deoxy-5-fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug.
Molecular pharmacology.
2001 Jun; 59(6):1542-8. doi:
10.1124/mol.59.6.1542. [PMID: 11353816] - W Scheithauer, G V Kornek, B Schuell, H Ulrich-Pur, M Penz, M Raderer, F Lang, B Schneeweiss, A Lenauer, D Depisch. Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy.
Annals of oncology : official journal of the European Society for Medical Oncology.
2001 May; 12(5):709-14. doi:
10.1023/a:1011194712661. [PMID: 11432632] - T Morita, A Matsuzaki, A Tokue. Enhancement of sensitivity to capecitabine in human renal carcinoma cells transfected with thymidine phosphorylase cDNA.
International journal of cancer.
2001 May; 92(3):451-6. doi:
10.1002/ijc.1212. [PMID: 11291085] - B Reigner, K Blesch, E Weidekamm. Clinical pharmacokinetics of capecitabine.
Clinical pharmacokinetics.
2001; 40(2):85-104. doi:
10.2165/00003088-200140020-00002. [PMID: 11286326] - C Twelves. Vision of the future: capecitabine.
The oncologist.
2001; 6 Suppl 4(?):35-9. doi:
10.1634/theoncologist.6-suppl_4-35. [PMID: 11585973]